Oncofetal fibronectin: new insight into the physiology of implantation and labor.
Oncofetal fibronectin is a newly studied protein produced by the trophoblast and is present in plasma and cervicovaginal secretions of pregnant women as labor approaches or when they have certain complications of pregnancy. Alterations in levels of oncofetal fibronectin occur in preterm labor, postterm pregnancy, and pregnancy-induced hypertension. Determining the presence or absence of full-term and preterm labor often is difficult in the clinical setting, and decision-making sometimes is hindered by the lack of a specific biochemical marker for labor. Oncofetal fibronectin may become a clinical indicator or predictor of true labor, preterm labor, or some complications of pregnancy. Assay techniques that identify clinically meaningful levels of oncofetal fibronectin are being developed and investigated and soon may be available to screen and identify pregnant women at risk. Research findings suggest new paths for investigation that may lead to important interventions in health care directed at identifying and decreasing maternal and neonatal morbidity and mortality. This article reviews pertinent aspects of placentation and the rationale for using oncofetal fibronectin detection as a clinical marker for abnormal pregnancy states.
Dunn
P A
PA
Hospital of the University of Pennsylvania, Philadelphia, USA.
Feinberg
R F
RF
D000249:Adenosine Monophosphate / Q000378:metabolism; D015415:Biomarkers; D010064:Embryo Implantation / Q000502:physiology*; D005260:Female; D005353:Fibronectins / Q000378:metabolism*; D006801:Humans; D007743:Labor, Obstetric / Q000378:metabolism*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000175:diagnosis / Q000378:metabolism
D015415:Biomarkers; D005353:Fibronectins; D000249:Adenosine Monophosphate